Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Cancer treatments using combinations of PI3K/Akt pathway and ERK inhibitors

Cancer treatments using combinations of PI3K/Akt pathway and ERK inhibitors

US Patent 11007183 · Granted May 18, 2021

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Use of bacteria, bacterial products, and other immunoregulatory entities in comb2025
Deuterated MK2 pathway inhibitors and methods of using the same2025
Methods of synthesizing substituted pyridinone-pyridinyl compounds2025
Oral compositions of MK2 pathway inhibitor for treatment of immune conditions2025
Crystalline forms of C21H22Cl2N4O22025
Cancer treatments using combinations of CDK and ERK inhibitors2024
Cancer treatments using combinations of CDK and ERK inhibitors2024
Cancer treatments using combinations of CDK and ERK inhibitors2024
Cancer treatments using combinations of CDK and ERK inhibitors2024
Anti-CD276 antibodies (B7H3)2023
Anti-CD276 antibodies (B7H3)2023
Anti-CD276 antibodies (B7H3)2023